scholarly article | Q13442814 |
P2093 | author name string | P K Duffner | |
J J MacKichan | |||
M E Cohen | |||
P2860 | cites work | CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients | Q34515320 |
Salivary levels of anticonvulsants: A practical approach to drug monitoring | Q39145895 | ||
Drug concentration in saliva | Q39212688 | ||
The binding of drugs by plasma proteins | Q39973717 | ||
Plasma and tissue protein binding of drugs in pharmacokinetics | Q40809296 | ||
Clinical Pharmacokinetics of Carbamazepine | Q40877361 | ||
A comparison of phenobarbitone and primidone in the control of seizures in chronic epilepsy [proceedings] | Q41045338 | ||
Carbamazepine: absorption, distribution, and excretion | Q44394933 | ||
The Pharmacokinetics of Carbamazepine in Plasma and Saliva of Man | Q44584927 | ||
Saliva carbamazepine levels in children | Q55184696 | ||
Plasma protein binding of carbamazepine | Q66918773 | ||
Anticonvulsant Level in Saliva, Serum, and Cerebrospinal Fluid | Q66956563 | ||
Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva | Q67274955 | ||
Carbamazepine for epilepsy. A controlled prospective evaluation | Q67288336 | ||
Carbamazepine: biotransformation | Q67373029 | ||
Distribution and elimination kinetics of carbamazepine in man | Q67396517 | ||
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses | Q67396551 | ||
Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations | Q67403367 | ||
Kinetics of carbamazepine and its 10,11‐epoxide metabolite in children | Q67443848 | ||
Carbamazepine and its 10,11-epoxide in children and adults with epilepsy | Q67549281 | ||
Studies on plasma protein binding of carbamazepine | Q68929708 | ||
Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy | Q69646920 | ||
Simultaneous liquid chromatographic analysis for carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva by use of double internal standardization | Q71242227 | ||
Physicochemical and Biochemical Aspects of Pharmacology | Q72348272 | ||
The comparative enzyme-inducing properties of antiepileptic drugs [proceedings] | Q95774218 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | carbamazepin | Q410412 |
P304 | page(s) | 31-37 | |
P577 | publication date | 1981-07-01 | |
P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
P1476 | title | Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients | |
P478 | volume | 12 |
Q50016064 | A descriptive systematic review of salivary TDM in neonates and infants |
Q41819119 | A simple collection method for saliva in children: potential for home monitoring of carbamazepine therapy |
Q40142216 | Anticonvulsant drugs. An update |
Q42094822 | Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants |
Q42531420 | Carbamazepine 10,11-epoxide in children |
Q67888965 | Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates |
Q39738819 | Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update |
Q40959033 | Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate |
Q42531581 | Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein |
Q42251696 | Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects |
Q93645811 | Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication |
Q39754383 | Free drug concentration monitoring in clinical practice. Rationale and current status |
Q69620797 | High-performance liquid chromatographic determination of carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva following solid-phase sample extraction |
Q39074126 | Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children |
Q41763892 | Progabide-induced changes in carbamazepine metabolism |
Q69395064 | Simultaneous quantitation of salivary carbamazepine, carbamazepine-10,11-epoxide, phenytoin and phenobarbitone by high-performance liquid chromatography |
Q34448173 | The effects of age on carbamazepine pharmacokinetics and adverse effects |
Q42873945 | The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results. |
Q33700135 | Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants |
Q35653966 | Therapeutic drug monitoring in saliva. An update |